G
Gujarat Inject Kerala
GUJINJEC BSE
Gujarat Inject Kerala
Healthcare BSE: GUJINJEC Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹187 Cr
Volatility
Moderate
P/E Ratio
60.7
EBITDA
₹2.31 Cr
Debt to Equity
0
Book Value
₹0.81
52W High
₹14.3
52W Low
₹1.9
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Growth Rate
Revenue Growth
89.17% ↗
Net Income Growth
81.00% ↗
Cash Flow Change
74.30% ↗
ROE
947.42% ↗
ROCE
911.29% ↗
EBITDA Margin (Avg.)
-3.06% ↗
Documents
Frequently Asked Questions about Gujarat Inject Kerala
Where is Gujarat Inject Kerala (GUJINJEC) listed?
Gujarat Inject Kerala is listed on the Indian stock exchanges. It is listed on BSE: GUJINJEC. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Gujarat Inject Kerala belong to?
Gujarat Inject Kerala operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Gujarat Inject Kerala?
Gujarat Inject Kerala has a market capitalisation of approximately ₹186.59 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Gujarat Inject Kerala?
The Price-to-Earnings (PE) ratio of Gujarat Inject Kerala is 60.70. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Gujarat Inject Kerala?
Over the past 52 weeks, Gujarat Inject Kerala has traded between a low of ₹1.9 and a high of ₹14.3. This range helps investors understand the stock's price volatility and recent trading levels.
How can I research Gujarat Inject Kerala on Tapetide?
On Tapetide, you can view Gujarat Inject Kerala's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.